Dendrogenix

Dendrogenix is a clinical-stage Belgian biotechnology company focused on developing a new class of anti-cancer agents called Dendrogenins. These are natural mammalian metabolites discovered by the company's founders that exhibit potent anti-tumor and pro-differentiation properties. The company's lead candidate, Dendrogenin A (DDA), is a first-in-class small molecule currently being evaluated in Phase 1/2 clinical trials for the treatment of acute myeloid leukemia and solid tumors. Dendrogenix aims to leverage its expertise in sterol metabolism to restore cell differentiation and immune surveillance in cancer patients. The company's research is rooted in the discovery that certain cholesterol-derived molecules are depleted in cancer cells, and their restoration can trigger tumor cell death. Beyond oncology, the company explores the potential of its platform in other therapeutic areas where sterol metabolism plays a critical role.